247 related articles for article (PubMed ID: 24554780)
1. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
[TBL] [Abstract][Full Text] [Related]
2. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
3. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA
Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840
[TBL] [Abstract][Full Text] [Related]
4. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
Roux PP; Richards SA; Blenis J
Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
[TBL] [Abstract][Full Text] [Related]
6. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.
Casalvieri KA; Matheson CJ; Backos DS; Reigan P
Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent and Selective RSK Inhibitors as Biological Probes.
Jain R; Mathur M; Lan J; Costales A; Atallah G; Ramurthy S; Subramanian S; Setti L; Feucht P; Warne B; Doyle L; Basham S; Jefferson AB; Lindvall M; Appleton BA; Shafer CM
J Med Chem; 2015 Sep; 58(17):6766-83. PubMed ID: 26270416
[TBL] [Abstract][Full Text] [Related]
8. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
9. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.
Abe Y; Yoon SO; Kubota K; Mendoza MC; Gygi SP; Blenis J
J Biol Chem; 2009 May; 284(22):14939-48. PubMed ID: 19332537
[TBL] [Abstract][Full Text] [Related]
10. Regulation and function of the RSK family of protein kinases.
Romeo Y; Zhang X; Roux PP
Biochem J; 2012 Jan; 441(2):553-69. PubMed ID: 22187936
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
12. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation.
Li P; Goto H; Kasahara K; Matsuyama M; Wang Z; Yatabe Y; Kiyono T; Inagaki M
Mol Biol Cell; 2012 Apr; 23(8):1582-92. PubMed ID: 22357623
[TBL] [Abstract][Full Text] [Related]
13. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
14. Paving the way for targeting RSK in cancer.
Romeo Y; Roux PP
Expert Opin Ther Targets; 2011 Jan; 15(1):5-9. PubMed ID: 20958120
[TBL] [Abstract][Full Text] [Related]
15. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
16. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
[TBL] [Abstract][Full Text] [Related]
17. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
18. Identification of RSK substrates using an analog-sensitive kinase approach.
Lizcano-Perret B; Vertommen D; Herinckx G; Calabrese V; Gatto L; Roux PP; Michiels T
J Biol Chem; 2024 Mar; 300(3):105739. PubMed ID: 38342435
[TBL] [Abstract][Full Text] [Related]
19. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
[TBL] [Abstract][Full Text] [Related]
20. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
